

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

**CHANGE IN CHIEF FINANCIAL OFFICER
AND APPOINTMENT OF CHIEF BUSINESS OFFICER**

The board of directors (the “**Board**”) of HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Weihao Xu (“**Mr. Xu**”) has been appointed as the chief financial officer and the chief business officer of the Company (the “**CFO**” and the “**CBO**”), with effect from the date of this announcement (the “**Effective Date**”).

As the CFO, Mr. Xu will be responsible for leading the overall management of the Company’s Finance, Public Relations and Investor Relations Department and overseeing all aspects of the Company’s financial operations. He is expected to manage the Group’s financial and business activities and develop and maintain relationships with existing and potential investors. In addition, he will initiate with his roles as the CBO, the Global Head of Business Development and Corporate Development of the Group and be responsible for developing and executing strategy for partnership and corporate investment, building innovation capabilities as well as an overall business ecosystem to drive growth.

Mr. Xu has more than 16 years of extensive experience in global capital markets, equity investment and financial management. Before joining the Group, Mr. Xu served as chief finance officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the portfolio manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments. Since joining the Company, Mr. Xu had led several collaboration projects which validated the Company’s global vision and strategy, including the global out-license agreement of HBM7022 with AstraZeneca, out-license agreement of HBM9161 with CSPC and out-license and collaboration agreement with Moderna.

Mr. Xu holds a master’s degree in Accounting and Financing from Columbia Business School. He also completed a certified program in High Impact Cancer Research from Harvard Medical School. The Board believes that Mr. Xu will make valuable contributions to the Group with his substantial leadership and financial experience.

The Board also announces that Dr. Yingying Chen (“**Dr. Chen**”) has relinquished her role as the CFO. Dr. Chen confirmed that she has no disagreement with the Board and that she was not aware of any matter in relation thereto that needed to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Chen for her contribution during her tenure serving as the CFO. The Board would like to extend its warm welcome to Mr. Xu on taking up the new positions in the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 11 November 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.